Cancer and Metastasis Reviews

Papers
(The TQCC of Cancer and Metastasis Reviews is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer268
The functions and modifications of tRNA-derived small RNAs in cancer biology144
Clonal tracking in cancer and metastasis118
Obesity and cancer117
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms90
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective89
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities84
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression67
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions60
Regulation of dormancy during tumor dissemination: the role of the ECM56
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor55
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?55
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations54
CAR T-cell therapy to treat multiple myeloma: current state and future directions53
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer53
Targeting lipid metabolism in cancer: neuroblastoma50
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?45
p73 isoforms meet evolution of metastasis45
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives44
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond42
Cell-cell interactions mediating primary and metastatic breast cancer dormancy41
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review40
A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients40
Biography—Mathieu Boissan, Pharm.D., Ph.D38
Preface36
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer34
Neuropeptide Y in cancer—biological functions and potential clinical implications34
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance33
Biographies32
The role of cancer cell bioenergetics in dormancy and drug resistance32
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance31
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy30
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications30
Short-chain fatty acids in cancer pathogenesis30
Clusterin: a marker and mediator of chemoresistance in colorectal cancer29
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis29
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy29
Vaping and tumor metastasis: current insights and progress28
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions28
Tumor necrosis factor superfamily signaling: life and death in cancer28
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy28
Clinical interventions to break the obesity and cancer link: a narrative review28
Carcinoma of unknown primary (CUP): an update for histopathologists28
The emerging roles of histone demethylases in cancers28
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development28
Functional and clinical roles of stromal PDGF receptors in tumor biology27
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution27
Kenneth V. Honn, Ph.D. (1946–2023)27
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy26
Inflammatory bowel disease and carcinogenesis26
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape26
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review26
New progress of tuberculosis scar carcinoma25
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting25
OX40/OX40 ligand and its role in precision immune oncology25
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective24
HOXA9 transcription factor is a double-edged sword: from development to cancer progression24
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies24
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases24
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect23
Ferroptosis: iron release mechanisms in the bioenergetic process23
Biographies23
Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX21
Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment21
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics21
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs21
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases21
1.1407051086426